Deutsche Bank Downgrades Omeros Corp. (OMER) to Hold; No Key Endpoints Were Met in Phase 3 Study

Deutsche Bank downgraded Omeros Corp. (NASDAQ: OMER) from Buy to Hold. Slashing PT from $13 to $6.

Deutsche analyst says, "We are downgrading Omeros shares to HOLD, following the announcement of negative Ph 3 results for OMS103HP, the co’s lead product candidate for improving outcomes in arthroscopic surgeries. And despite the disappointing data, we continue to believe in the viability of OMER’s PharmacoSurgery platform (OMS103HP, OMS302, OMS201) given positive clinical results from other trials to date. Hence, we are projecting a 2 year delay for OMS103HP–assuming the successful completion of clinical testing in meniscectomy surgery."

For more ratings news on Omeros Corp. click here and for the rating history of Omeros Corp. click here.

Shares of Omeros Corp. closed at $8.00 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Deutsche Bank Downgrades Workday (WDAY) to Hold
• Phillip Securities Downgrades Shopify (SHOP) to Accumulate
• Keefe, Bruyette & Woods Downgrades Crescent BDC (CCAP) to Market Perform